AR007766A1 - Derivados de bifenilcarbonil heterociclo espiro piperidinil indolina sustituidos, procedimiento para su preparacion, su uso para prepararcomposiciones farmaceuticas y una composicion farmaceutica que los contiene - Google Patents
Derivados de bifenilcarbonil heterociclo espiro piperidinil indolina sustituidos, procedimiento para su preparacion, su uso para prepararcomposiciones farmaceuticas y una composicion farmaceutica que los contieneInfo
- Publication number
- AR007766A1 AR007766A1 ARP970101069A ARP970101069A AR007766A1 AR 007766 A1 AR007766 A1 AR 007766A1 AR P970101069 A ARP970101069 A AR P970101069A AR P970101069 A ARP970101069 A AR P970101069A AR 007766 A1 AR007766 A1 AR 007766A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- group
- indoline
- piperidinyl
- Prior art date
Links
- KZEACTUUYFWAFO-UHFFFAOYSA-N 1-piperidin-1-yl-2,3-dihydroindole Chemical compound C1CC2=CC=CC=C2N1N1CCCCC1 KZEACTUUYFWAFO-UHFFFAOYSA-N 0.000 title 1
- -1 OF BIPHENYL CARBONYL Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 13
- 229910052739 hydrogen Inorganic materials 0.000 abstract 11
- 239000001257 hydrogen Substances 0.000 abstract 11
- 150000002431 hydrogen Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229920006395 saturated elastomer Polymers 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 101000869592 Daucus carota Major allergen Dau c 1 Chemical group 0.000 abstract 2
- 101000650136 Homo sapiens WAS/WASL-interacting protein family member 3 Chemical group 0.000 abstract 2
- 102100027539 WAS/WASL-interacting protein family member 3 Human genes 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Abstract
Comprenden la fórmula (I) o una sal o hidróxido del mismo, en la que: R es un grupo NR1COR2 en el que R1 es hidrógeno, alquilo de C1-6 o junto con R3forma un grupo (CH2)k en el que k es 2, 3 o 4, y R2 es hidrógeno, alquilo de C1-6 o arilo opcionalmente sustituido; o R es un anillo heterocíclico bicíclicosaturado o parcialmente saturado, opcionalmente sustituido, o un anillo heterocíclico monocíclico de 5 a 7 miembros, saturado o parcialmente saturado,que contiene 1 a 4 heteroátomos seleccionados entre oxígeno, nitrógeno o azufre; R4 y R5 son independientemente hidrógeno, halógeno, alquilo de C1-6,cicloalquilo de C3-6, cicloalquenilo de C3-6, alcoxi de C1-6, hidroxialquilo de C1-6, alquilo de C1-6 o alquilo de C1-6, acilo, arilo, aciloxi, hidroxi, nitro,trifluorometilo, ciano CO2R11, CONR12R13, NR12R13, en los que R11, R12 y R13 son independientemente hidrógeno o alquilo de C1-6, o R4 y R5 juntamente formanun grupo -(CH2)r-R14-(CH2)s- en el que R14 es O, S, CH2o NR15 en el que R15 es hidrógeno o alquilo de C1-6 y r y s son independientemente 0, 1 o 2; B esoxígeno o azufre; D es nitrógeno, carbono o un grupo CH; R6 es hidrógeno o alquilo de C1-6 y R7 es hidrógeno, alquilo de C1-6, alcoxi de C1-6 o halógeno,o R6 junto con R7 forma un grupo -A- en el que A es (CR16R17)t en el que t es 2, 3 o 4 y R16 y R17 son independientemente hidrógeno o alquilo de C1-6 o A es(CR16R17)u-J en el que u es 0, 1, 2 o 3 y J es oxígeno, azufre, CR16=CR17, CR16=N, =CR16O, =CR16S o =CR16-NR17; R8 es hidrógeno, alquilo de C1-6,cicloalquilo de C3-6, alquenilo de C2-6 o alquilo de C1-6 cicloalquilo de C3-6; R9 y R10 son independientemente hidrógeno o alquilo de C1-6; E esoxígeno, CR18R19 o NR20, en el que R18, R19 y R20 son independientemente hidrógeno o alquilo de C1-6 o E es S(O)v en el que v es 0, 1 o 2; G es C=O o
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9605883.9A GB9605883D0 (en) | 1996-03-20 | 1996-03-20 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR007766A1 true AR007766A1 (es) | 1999-11-24 |
Family
ID=10790741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970101069A AR007766A1 (es) | 1996-03-20 | 1997-03-18 | Derivados de bifenilcarbonil heterociclo espiro piperidinil indolina sustituidos, procedimiento para su preparacion, su uso para prepararcomposiciones farmaceuticas y una composicion farmaceutica que los contiene |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6100272A (es) |
| EP (1) | EP0888358A1 (es) |
| JP (1) | JP2000507240A (es) |
| AR (1) | AR007766A1 (es) |
| AU (1) | AU2158197A (es) |
| CA (1) | CA2250016A1 (es) |
| GB (1) | GB9605883D0 (es) |
| ID (1) | ID16373A (es) |
| PE (1) | PE56198A1 (es) |
| UY (1) | UY24491A1 (es) |
| WO (1) | WO1997034901A1 (es) |
| ZA (1) | ZA972329B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2297943T3 (es) | 1998-12-23 | 2008-05-01 | Aventis Pharma Limited | Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas. |
| WO2001064213A1 (en) * | 2000-03-02 | 2001-09-07 | Smithkline Beecham Corporation | Compounds and methods |
| ES2316777T3 (es) | 2002-02-15 | 2009-04-16 | Glaxo Group Limited | Moduladores de receptores vainilloides. |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
| WO2025039999A1 (zh) * | 2023-08-18 | 2025-02-27 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类化合物、其制备方法及其在医药上的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2162792T3 (es) * | 1991-09-18 | 2002-01-16 | Glaxo Group Ltd | Derivados de benzanilida como antagonistas de 5-ht1d. |
| GB9119920D0 (en) * | 1991-09-18 | 1991-10-30 | Glaxo Group Ltd | Chemical compounds |
| FR2699918B1 (fr) * | 1992-12-30 | 1995-03-17 | Pf Medicament | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. |
| GB9326008D0 (en) * | 1993-12-21 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
| EP0670313A1 (en) * | 1994-03-04 | 1995-09-06 | Takeda Chemical Industries, Ltd. | Spiro compounds, their production and use |
| GB9421003D0 (en) * | 1994-10-18 | 1994-12-07 | Smithkline Beecham Plc | Novel compounds |
| JPH10510821A (ja) * | 1994-12-22 | 1998-10-20 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 四環式スピロ化合物、その製法およびその５ｈｔ１ｄレセプターアンタゴニストとしての使用 |
| GB9519033D0 (en) * | 1995-09-18 | 1995-11-15 | Smithkline Beecham Plc | Treatment |
| FR2761069A1 (fr) * | 1997-03-20 | 1998-09-25 | Pf Medicament | Spiroamines derivees de dihydrobenzofuranes, leur preparation et leur application comme medicaments |
-
1996
- 1996-03-20 GB GBGB9605883.9A patent/GB9605883D0/en active Pending
-
1997
- 1997-03-18 ZA ZA972329A patent/ZA972329B/xx unknown
- 1997-03-18 AR ARP970101069A patent/AR007766A1/es unknown
- 1997-03-18 PE PE1997000202A patent/PE56198A1/es not_active Application Discontinuation
- 1997-03-18 UY UY24491A patent/UY24491A1/es unknown
- 1997-03-18 ID IDP970881A patent/ID16373A/id unknown
- 1997-03-19 AU AU21581/97A patent/AU2158197A/en not_active Abandoned
- 1997-03-19 WO PCT/EP1997/001404 patent/WO1997034901A1/en not_active Ceased
- 1997-03-19 CA CA002250016A patent/CA2250016A1/en not_active Abandoned
- 1997-03-19 US US09/142,988 patent/US6100272A/en not_active Expired - Fee Related
- 1997-03-19 JP JP9533157A patent/JP2000507240A/ja active Pending
- 1997-03-19 EP EP97914271A patent/EP0888358A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997034901A1 (en) | 1997-09-25 |
| PE56198A1 (es) | 1998-12-10 |
| ZA972329B (en) | 1998-09-18 |
| UY24491A1 (es) | 1997-09-12 |
| US6100272A (en) | 2000-08-08 |
| GB9605883D0 (en) | 1996-05-22 |
| CA2250016A1 (en) | 1997-09-25 |
| AU2158197A (en) | 1997-10-10 |
| JP2000507240A (ja) | 2000-06-13 |
| EP0888358A1 (en) | 1999-01-07 |
| ID16373A (id) | 1997-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050265A1 (es) | Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1) | |
| CO4950609A1 (es) | Nuevos compuestos | |
| AR013076A1 (es) | Nuevos compuestos de piperazina, un procedimiento para su preparacion y una composicion farmaceutica que los comprende | |
| PE20020366A1 (es) | Derivados de piperazina como ligandos del receptor 5ht2 | |
| AR048362A1 (es) | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos | |
| NO952208L (no) | Amin-derivater | |
| AR002011A1 (es) | Compuestos derivados de piperidina, sus sales y n-oxidos, procedimiento de preparacion y composiciones farmaceuticas. | |
| AR036111A1 (es) | Compuesto de n-[alfa-aminoalcanoil]-3-fluorpirrolidina; composicion farmaceutica formulada con dicho compuesto; su uso en la preparacion de dicha composicion y metodo para el tratamiento de la diabetes tipo 2 utilizando dicho compuesto | |
| PE20020257A1 (es) | Derivados biciclicos sustituidos como inhibidores de la proteina tirosina cinasa | |
| CY1108091T1 (el) | Βιολογικως ενεργα παραγωγα μπλε του μεθυλενιου | |
| ES2059327T3 (es) | Derivados de tetrahidronaftaleno y de indano, obtencion de los mismos y utilizacion en preparados farmaceuticos. | |
| AR039562A1 (es) | Compuestos oxo-azabiciclicos | |
| AR012622A1 (es) | Inhibidores de proteasas, procedimiento para su preparacion, composicion farmaceutica que los comprende y el uso de los mismos en la fabricacion de unmedicamento | |
| PE20021018A1 (es) | DERIVADOS DE ß - CARBOLINA | |
| ES2038678T3 (es) | Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos. | |
| AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
| AR027744A1 (es) | Compuestos de eter difenilico utiles en terapia | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR007766A1 (es) | Derivados de bifenilcarbonil heterociclo espiro piperidinil indolina sustituidos, procedimiento para su preparacion, su uso para prepararcomposiciones farmaceuticas y una composicion farmaceutica que los contiene | |
| AR013152A1 (es) | Derivados de 2-alquilheterodihidropirimidina, proceso para su preparacion, composiciones farmaceuticas que contienen dichos derivados y el uso de dichosderivados y composiciones como ligandos para canales de calcio neuronales de tipo n. | |
| BG60338B2 (en) | Thienothiazines | |
| PE20020599A1 (es) | Derivados de acido amino-furan-2-il-acetico sustituido o de acido amino-tien-2-il-acetico sustituido, procedimiento para su preparacion, medicamentos que los contienen, uso de estos compuestos para la preparacion de medicamentos para el tratamiento d | |
| Ashford et al. | Synthesis and in vitro evaluation of tetrahydroisoquinolines with pendent aromatics as sigma-2 (σ 2) selective ligands | |
| DE69520279D1 (de) | Bibphenylamid-derivate als 5-ht1d-antagonisten | |
| ES515904A0 (es) | "procedimiento para preparar nuevas triazoloquinazolonas". |